|
End-of-day quote
Dhaka S.E.
02/11/2026
|
5-day change | 1st Jan Change | ||
| 142.10 BDT | -1.52% |
|
-2.67% | +39.18% |
| 10-29 | Beximco Pharmaceuticals plc announces Annual dividend | CI |
| 10-01 | Beximco Pharmaceuticals Reaches Settlement With Bangladeshi Regulator Over Board Restructuring | MT |
| Market Cap | 63.39B 510M 455M 418M 380M 712M 48.27B 727M 4.99B 2.01B 25.48B 1.91B 1.87B 80.47B | P/E 2026 |
6.97x | P/E 2027 * | 6.39x |
|---|---|---|---|---|---|
| Enterprise Value | 63.39B 510M 455M 418M 380M 712M 48.27B 727M 4.99B 2.01B 25.48B 1.91B 1.87B 80.47B | EV / Sales 2026 |
-
| EV / Sales 2027 * | 1.03x |
| Free-Float |
85.91% | Yield 2026 * |
4.24% | Yield 2027 * | 4.85% |
| 1 day | -1.52% | ||
| 1 week | -2.67% | ||
| Current month | -1.11% | ||
| 1 month | -3.46% | ||
| 3 months | -5.83% | ||
| 6 months | +23.78% | ||
| Current year | +39.18% |
| 1 week | 141.7 | 145.8 | |
| 1 month | 138.5 | 147.9 | |
| Current year | 99.5 | 158.5 | |
| 1 year | 99.5 | 158.5 | |
| 3 years | 64.2 | 158.5 | |
| 5 years | 64.2 | 234 | |
| 10 years | 47.36 | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 04/03/2024 |
| Director of Finance/CFO | 63 | 01/01/2003 | |
Mohammad Haque
ADM | Chief Administrative Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 19/06/2009 | |
| Director/Board Member | - | 01/02/2010 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 01/01/1985 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.52% | -2.67% | +21.66% | -2.80% | 519M | ||
| -0.46% | +10.80% | +63.52% | +154.48% | 1,263B | ||
| -0.97% | +2.56% | +43.25% | +81.96% | 658B | ||
| -2.05% | +1.12% | +32.47% | +102.74% | 521B | ||
| -1.54% | +1.61% | +53.42% | +67.10% | 391B | ||
| -0.78% | +2.13% | +72.55% | +44.25% | 369B | ||
| -1.69% | +2.75% | +32.49% | +54.35% | 307B | ||
| -0.72% | +8.08% | +11.15% | +34.09% | 290B | ||
| -0.12% | +5.96% | +55.97% | +78.44% | 252B | ||
| -0.21% | +9.16% | +42.19% | +112.41% | 212B | ||
| Average | -0.69% | +5.26% | +42.87% | +72.70% | 426.24B | |
| Weighted average by Cap. | -0.45% | +6.60% | +49.14% | +97.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.78B 441M 393M 361M 328M 616M 41.71B 628M 4.31B 1.74B 22.02B 1.65B 1.62B 69.54B | 61.27B 493M 440M 404M 367M 689M 46.65B 702M 4.82B 1.94B 24.62B 1.85B 1.81B 77.77B |
| Net income | 8.66B 69.66M 62.2M 57.07M 51.92M 97.34M 6.6B 99.28M 682M 275M 3.48B 261M 256M 10.99B | 9.92B 79.77M 71.22M 65.36M 59.45M 111M 7.55B 114M 781M 315M 3.99B 299M 293M 12.59B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/11/26 | BDT 142.10 | -1.52% | 386,700 |
| 01/11/26 | BDT 144.30 | +0.42% | 381,201 |
| 29/10/26 | BDT 143.70 | +0.49% | 473,934 |
| 28/10/26 | BDT 143.00 | +0.14% | 312,831 |
| 27/10/26 | BDT 142.80 | -1.24% | 700,170 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
















